Tag - MCRB

Developments

Seres SER-109 meets primary endpoint in Phase 3 study of C. difficile infection

Seres Therapeutics (NASDAQ:MCRB) reported positive topline results from its Phase 3 trial evaluating SER-109 for the treatment of recurrent C. difficile infection. The study enrolled 182 patients with multiply...

August 10, 2020

Developments

Seres Therapeutics in microbiome immuno-oncology collaboration with AstraZeneca

Seres Therapeutics (NASDAQ:MCRB) entered a three-year research collaboration with AstraZeneca to focus on advancing the understanding of the microbiome in augmenting the efficacy of cancer immunotherapy, including...

March 11, 2019

Tag - MCRB

Seres SER-109 meets primary endpoint in Phase 3 study of C. difficile infection

Seres Therapeutics in microbiome immuno-oncology collaboration with AstraZeneca

General

More